Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to 20 programs.
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...
Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback